[Turn] Giant's fight!Pfizer's new crown vaccine defendant infringement

Source: Siqi Club/Four Leaf

Modner sued Pfizer and BIONTECH, saying that his new crown vaccine violated Modner MRNA technology patent.

On August 26 local time, Moderna, the United States, officially sued Pfizer and Biontech, a German partner, on the grounds that they infringed patent rights when developing the first new crown vaccine.

Litigation involves two types of patents

Modner said that the new crown vaccine developed by Pfizer and Biontech violated the patent applied for MRNA technology from MRNA technology between 2010 and 2016. This technology is the core technology of developing Modner's new crown vaccine "Spikevax".

The lawsuit mainly involves two types of patents, one of which involves the MRNA structure and the other involves full -length spiny protein. For the second type of patent, Modner said that his scientists have developed this protein while developing (Middle East Respiratory Syndrome) MERS vaccine, which is quite helpful for its rapid development of new crown vaccines.

According to Modner's allegations, Pfizer and Biontech's new crown vaccine "Comingaty" was developed by "copying" Modner's technology without Modner's permission.

Modner CEO Stana Bangseles said in a statement that before the new crown epidemic, Modner had invested billions of dollars to develop MRNA technology, and filed a lawsuit to protect the company's scientific and technological innovation.

It is worth mentioning that in the early days of the new crown epidemic, Modner promised that it would not enforce its intellectual property rights during the period. However, on March 7 this year, Modner changed his mouth to say that it was only suitable for low -income countries.

Modner said that the purpose of the prosecution is to want other companies to respect Modner's intellectual property rights, and will not seek the "infringement" vaccine of Pfizer and Biontech from the market, nor will it prevent their sales. Modner stated that it will seek patent fees based on the sales of vaccines after March 8, 2022, but the charge will exclude some of the vaccine sales of some low -income countries. In this lawsuit, Modner did not mention the specific claim amount.

In this regard, Pfizer and Biontech responded quickly and did not recognize it. Pfizer issued a statement saying that Modner's lawsuit was "surprised" and stated that the technology used by its new crown vaccine was jointly developed by Pfizer and Biontech, and the company would "resolutely safeguard its own rights and interests."

The vaccine competition enters the second half

Pfizer and Modner's new crown vaccine is the two most widely used new crown vaccines in the United States. In December 2020, it was authorized by FDA. According to statistics from the US Centers for Disease Control and Prevention, since the outbreak, about 360 million Pfizer vaccines have been vaccinated in the United States and about 230 million Modner vaccines.

In fact, whether it is Pfizer or Modner, they have made huge profits from the new crown vaccine. Pfizer achieved nearly $ 37 billion in sales last year, while Modner achieved approximately $ 18 billion in revenue. In the first half of this year, the revenue of the new crown vaccine was further increasing, and Pfizer and Modner's new crown vaccine revenue reached US $ 22 billion and $ 10.4 billion, respectively.

It should be pointed out that before the development of the new crown vaccine, Modner and Biontech were two start -up biotechnology companies that did not have any commercial products. They only rely on the new crown vaccine products or MRNA technology to promote the company to achieve a leap development development. Essence

Recently, it is reported that the United States will cancel the public support of the new crown drugs and vaccines. At this time, the two new crown vaccine companies will start a patent war. It is also worth thinking about. At the same time, they are also competing for the next -generation updated version of the market share of the Omikon mutation.

Last Tuesday, Modner submitted a secondary price to strengthen vaccine applications for the US FDA for Omikon BA.4/BA.5 mutant strain and the new primitive strain. The day before Modner announced the news, Pfizer and Biontech also submitted an authorization application for binary vaccine reinforcements to the US FDA.

In addition, industry insiders believe that the true purpose of the prosecution of the new crown vaccine patent right is the long -term development of the enterprise. In addition to the vaccine, MRNA technology will be applied in many fields in the future, especially in the field of tumor therapy, which has considerable potential.

Disclaimer: This article is the content of Yaozhi.com, and the copyright of the pictures and text belongs to the original author. The purpose of reprinting is to pass more information, which does not represent the viewpoint of this platform. If the content, copyright and other issues are involved in the work, please leave a message on this platform, and we will delete it as soon as possible.

- END -